Loading patent…
AssigneeElan Pharmaceuticals, Inc.
InventorsTamie J Chilcote, Jason Goldstein, John P Anderson, Donald Walker
Estimating the term…
The application identifies novel fragments of alpha-synuclein in patients with Lewy Body Disease (LBD) and transgenic animal models thereof. These diseases are characterized by aggregations of alpha-synuclein. The fragments have a truncated C-terminus relative to full-length alpha-synuclein. Some fragments are characterized by a molecular weight of about 12 kDa as determined by SDS gel electrophoresis in tricine buffer and a truncation of at least ten contiguous amino acids from the C-terminus of natural alpha-synuclein. The site of cleavage preferably occurs after residue 117 and before residue 126 of natural alpha-synuclein. The identification of these novel fragments of alpha-synuclein has a number of application in for example, drug discovery, diagnostics, therapeutics, and transgenic animals.
A method of screening for an agent having a pharmacological activity useful for treating a Lewy Body Disease (LBD) comprising:
A purified fragment of alpha synuclein, which is SN1-115, SN1-133 or SN 1-135, with residues defined by SEQ ID NO:1 or a hereditary variant thereof associated with Lewy Body disease, or an induced variant thereof selected from the group consisting of E83Q, A90V and A76T.
A fragment of alpha synuclein which is SN1-115, SN1-133 or SN 1-135, with residues defined by SEQ ID NO:1, or a hereditary variant thereof associated with Lewy body disease, or a or an induced variant thereof selected from the group consisting of E83Q, A90V and A76T, which fragment is recombinantly expressed or synthesized by solid phase peptide synthesis.
Dependencies are inferred from the claim text.